Evidence map›Paper›PMID 36336518›Full record

ArticleMayo Clinic proceedings2022

Relative Survival With Early-Stage Breast Cancer in Screened and Unscreened Populations.

Andrea R Marcadis, Luc G T Morris, Jennifer L Marti

Open access · greenAbstract read
In one paragraph

Article in Mayo Clinic proceedings, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. International journal of molecular sciences · 2023
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Andrea R MarcadisDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Luc G T MorrisDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jennifer L MartiWeill Cornell Breast Center, Department of Surgery, Weill Cornell Medicine, New York, NY, USA. Electronic address: drjennifer.marti@gmail.com.
Memorial Sloan Kettering Cancer Center · USWeill Cornell Medicine · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
HEAD AND NECK TRAINING PROGRAM SURGICAL ONCOLOGYT32CA009685 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI FAGIN, JAMES A, WONG, RICHARD J · 1992 to 2022
$3.6M
Identifying and targeting neoantigens in aggressive salivary carcinomasR01DE027738 · NIDCR · SLOAN-KETTERING INST CAN RESEARCH · PI CHAN, TIMOTHY AN-THY, HO, ALAN L. · 2018 to 2022
$2.8M
Functionalizing recurrent FAT1 mutations and deletions in oral cancerK08DE024774 · NIDCR · SLOAN-KETTERING INST CAN RESEARCH · PI MORRIS, LUC GORDON TRANG · 2014 to 2018
$682k
NCI NIH HHS P30 CA008748NCI NIH HHS T32 CA009685NIDCR NIH HHS K08 DE024774NIDCR NIH HHS R01 DE027738
6 · The paper itself

Abstract

Relative survival and disease-specific survival are two statistics that measure net survival from a cancer diagnosis, excluding other causes of death. In most cases, these two rates are comparable. However, in some cancer types for which cancer screening is performed, relative survival is often greater than disease-specific survival. This divergence has been attributed to mechanisms such as the "healthy user effect" and overdiagnosis of indolent tumors detected by screening. Using relative survival rate as a marker of these mechanisms, we examined the association of breast cancer screening with relative survival rates for women diagnosed with early-stage breast cancer. In population-based data from the National Cancer Institute's Surveillance, Epidemiology and End Results registry, we examined relative survival rates in women diagnosed with stage I breast cancer or ductal carcinoma in situ who were in highly screened vs less-highly screened groups, based on time period, age group, and insurance status. In this analysis, relative survival rates for early-stage breast cancer were higher than disease-specific survival, even exceeding 100% in populations experiencing higher rates of screening (ie, women diagnosed during the era of widespread uptake of mammography, age older than 40 years, and women with health insurance coverage). The favorable outcomes observed in screen-detected breast cancers are at least in part attributable to the healthy user effect and overdiagnosis of indolent tumors. Therefore, survival rates may not accurately reflect the effectiveness of cancer screening. These findings have implications for counseling of patients and future clinical studies of active monitoring approaches in breast cancer.

Indexed as

Breast NeoplasmsCarcinoma, Intraductal, NoninfiltratingAdultEarly Detection of CancerFemaleHumansMammographyMass Screening

Identifiers

PMID36336518
PMCPMC10314986
OpenAlexW4308368737

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.